Journal
JOURNAL OF DRUG TARGETING
Volume 28, Issue 9, Pages 861-872Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/1061186X.2020.1737934
Keywords
Targeted therapy; epidermal growth factor receptor; pathogenic mutations; epidermal growth factor receptor-tyrosine kinase inhibitors; non-small cell lung carcinoma
Categories
Funding
- National Natural Science Foundation of China [NSFC 81472787, 81773671, 81828010]
- CAMS Innovation Fund for Medical Sciences [CIFMS 2016-I2M-3013]
- Drug Innovation Major Project of China [2018ZX09711001-007-002]
Ask authors/readers for more resources
Non-small cell lung carcinoma (NSCLC) is a malignant tumour with poor prognosis and high mortality. Platinum-based dual-agent chemotherapy is the main therapeutic regimen for this disease. In recent years, because of the introduction of molecular targeted therapy, various targeted therapeutic agents against epidermal growth factor receptor (EGFR) have been rapidly developed, which has become a research hotspot for NSCLC treatment. Here, we review the latest studies describing the features and types of EGFR pathogenic mutations, currently established EGFR-tyrosine kinase inhibitors from the first to fourth generation, including their action mechanisms, acquired resistance, and clinical applications, and potential challenges and perspectives that current researchers should address.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available